It used to be that lymphoma specialists believed that how a patient responded to a particular treatment was almost entirely dependent on the lymphoma itself–what kind of mutations it had, what its growth rate was, and so on. These days, however, researchers have come to realize that the “microenvironment” surrounding lymphoma is almost as important to a patient’s outcome as the lymphoma itself. In this interview with Patient Power’s Andrew Schorr, Dr. Oliver Press describes the various components of this microenvironment and how manipulating it might help to more effectively kill lymphoma cells.
Listed below are clinical trials that have opened at SCCA in the last several weeks. These trials are looking at new treatments for patients with prostate cancer, metastatic Merkel cell carcinoma, advanced solid tumors, and recurrent thoracic cancers. For more information about these trials, click on the links below. Check out our website to learn about the more than 200 ongoing clinical trials at SCCA. And follow us on Twitter at @SCCA_Trials for information about recently opened trials.
Seizure Risk Evaluation of Patients Treated with Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
MSB0010718C for Metastatic Merkel Cell Carcinoma
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects With Merkel Cell Carcinoma
ME-344 in Combination With Hycamtin® for Solid Tumors
A Phase Ib Open-Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
PF-05082566 Plus MK-3475 for Advanced Solid Tumors
A Phase I Study Of The 4-1BB Agonist PF-05082566 in Combination With The PD-1 Inhibitor MK-3475 in Patients With Advanced Solid Tumors
Proton Beam Radiation Therapy for Recurrent Thoracic Cancer (9148)
Definitive Re-Irradiation With Proton Beam Radiotherapy for Patients With Recurrent Thoracic Cancers
Women who have dense breast tissue not only have a higher risk of developing breast cancer, but their dense tissue is also more likely to mask the presence of cancer on a typical screening mammogram. Today, the journal Radiology published a study conducted by researchers at SCCA and the University of Washington that found that adding tomosynthesis (also known as 3D mammography) to routine biennial digital mammography could improve health outcomes at a reasonable cost relative to digital mammography alone. For this study, the team used data and metrics from the National Cancer Institute’s Breast Cancer Surveillance Consortium to compare the clinical- and cost-effectiveness of biennial screening with both digital mammography and 3D mammography versus digital mammography alone. Learn more about the study here.
SCCA is also conducting a clinical study for women with dense breast tissue that looks at 3D mammography and automated breast ultrasound compared with standard digital mammography. If you have dense breast tissue and would like more information about taking part in this study, including eligibility requirements, see the Screening Tomosynthesis and Automated Breast Ultrasound Research (STAR) study on our website or call SCCA at (206) 288-6321.
Abnormal mammogram image courtesy of the NCI; Mitchell D. Schnall, M.d., Ph.D. University of Pennsylvania.
Movember is a worldwide movement aimed at raising awareness for prostate cancer and men’s health. The idea is for guys to shave their face on November 1 (or Movember 1) and grow a moustache for the month. Individually and collectively, all those moustaches (or mo’s as they’re called) become talking points for men’s health and a way to raise awareness and funds to support men’s health initiatives and research.
To help mobilize support for Movember, the doctors here at SCCA and UW Urologic Oncology, led by Dr. Jonathan Wright, invite you to join their team and become a MoDAWG.
Here’s how to get started:
- Register to become a MoDAWG as a Mo Bro or Mo Sista.
- Recruit others.
- If you’re a Mo Bro, grow your mustache starting on November 1, or shave what you’ve got and start growing it again. View the rules and style tips here.
- Start talking up men’s health and ask the men around you if they have had their annual health check up and, if they’re over 40, a PSA test.
Watch this space for mo-developments as we move through Movember. Finally, see the video below for how we finished up Movember last year.
Editor’s Note: Dr. Julie Gralow is the director of Breast Medical Oncology at SCCA. In celebration of Breast Cancer Awareness Month, we’ve asked Dr. Gralow to answer readers’ questions about breast cancer every Friday during October. If you have a question that you would like to ask Dr. Gralow, please let us know.
This week Dr. Gralow is in Chicago attending the SWOG Fall 2014 Group Meeting. SWOG is a cancer research cooperative group that designs and conducts multidisciplinary clinical trials. So it’s appropriate that she takes on this week’s question: “What are the latest developments in breast cancer research?” In this video, Dr. Gralow talks about four promising areas of research: CDK 4/6 inhibitors, PARP inhibitors, androgen receptors, and immunotherapy.